Loading market dashboard
HLS Therapeutics Inc.
HLTRFHealthcareOTCCA
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
HLS Therapeutics TSE: HLS reported modest first-quarter revenue growth and reaffirmed its 2026 outlook, while management highlighted early momentum for the company's newly launched cholesterol drug NILEMDO and continued deleveraging of its balance sheet.
HLS Therapeutics Inc. (HLS:CA) Q4 2025 Earnings Call Transcript
